Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation (BRACE-AFib)

12 novembre 2026 aggiornato da: University Hospital, Basel, Switzerland

BRACE-AFib: Beta-blocker Replacement and Calcium Channel Blockers Evaluation in Atrial Fibrillation

Beta-blockers are generally prescribed for the treatment of atrial fibrillation. Their purpose is to slow the heart rate and thereby reduce the workload on the heart. However, beta-blockers can affect patients' quality of life, for example by reducing physical performance or causing fatigue in daily life.

the aim of this study is to determine whether calcium channel blockers can improve the treatment of atrial fibrillation and have a positive impact on the quality of life of patients with atrial fibrillation compared with beta-blockers. It will also be investigated how calcium channel blockers affect the physical exercise capacity. In addition, potential side effects of both medications will be monitored and it will be explored whether there are any differences between women and men over the course of the study.

Both study medications, the calcium channel blocker diltiazem and the beta-blocker bisoprolol, are approved by authorities and are recommended by the European Society of Cardiology for rate control in atrial fibrillation.

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. Many AF patients present with a rapid ventricular response resulting in a high heart rate (HR). In these patients, it is important to lower the HR. To achieve rate control, several pharmacological agents are available, but beta-blockers (BB) are predominantly used. There is little evidence supporting the preference for BB. Side effects of BB such as fatigue, dizziness, and effort intolerance are widely known. Non-dihydropyridine calcium channel blockers (NDCC) represent an alternative for rate control and might be associated with better quality of life (QoL) than BB in AF patients. This study aims to investigate the impact on the QoL of AF patients who are currently on BB therapy and are switching to NDCC. Both men and women affected by AF and its complications will be enrolled in the study.

If this study can show an advantage of NDCC over BB in AF patients, a paradigm shift in the treatment of AF could take place. This could mean an easily implementable potential therapeutic advantage at no supplementary cost for patients and the health care system. Given the very common use of BB in AF patients, the negative impact of this drug on QoL could affect thousands of patients.

The investigational medicinal product (IMP) is diltiazem, a NDCC. Diltiazem belongs to the benzothiazepine class and exerts its pharmacological effect through inhibition of L-type calcium channels in atrioventricular nodal tissue, resulting in negative dromotropic effects and effective ventricular rate control in AF. Diltiazem is approved by the authorities and recommended by current guidelines as an alternative to BB for rate control in AF.

In the present study, diltiazem is administered orally in a prolonged-release formulation at daily doses of 90 mg, 180 mg, or 360 mg, corresponding to low, normal, or high dose categories. The comparator is bisoprolol, a β1-selective beta-adrenergic receptor blocker. BB are the most frequently prescribed agents for rate control in AF and represent the current standard of care. Bisoprolol is administered orally at daily doses of 2.5 mg, 5 mg, or 10 mg, reflecting standard clinical practice.

Patient representatives have been involved in developing our research from the beginning. Their insights have guided our approach to ensure the study addresses real concerns faced by patients affected by AF.

Tipo di studio

Interventistico

Iscrizione (Stimato)

266

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Canton of Basel-City
      • Basel, Canton of Basel-City, Svizzera, 4031
        • University Hospital Basel
        • Investigatore principale:
          • Patrick Badertscher, PD Dr. med.
        • Contatto:
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Documented AF
  • Currently on a stable regimen of BB for at least three weeks
  • Informed consent as documented by signature

Exclusion Criteria:

  • Left ventricular ejection fraction (LVEF) <40%
  • Severe valvular heart disease
  • Uncontrolled hypertension defined as systolic BP > 180 mmHg
  • AV block Type II, AV block type III
  • Severe bradycardia, defined as a resting heart rate <40 bpm on ECG
  • Currently on a NDCC (Diltiazem or Verapamil)
  • Concomitant rhythm-controlling medication (antiarrhythmic drugs Vaughan Williams classification I and III)
  • Currently on Ivabradine, Digoxin, Clonidine, Pimozide, Dihydroergotamine, Nifedipine, Lomitapide
  • History of atrio-ventricular node ablation
  • Implanted pacemaker or implantable cardioverter defibrillator (ICD) with a right-ventricular pacing burden >40%
  • Previous pulmonary vein isolation (PVI) or electric cardioversion within 90 days prior to study enrolment
  • Established infiltrative myocardial disease, e.g. amyloidosis, constrictive pericarditis, myocarditis, hypertrophic cardiomyopathy
  • End-stage renal disease, estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2
  • Pregnant or breastfeeding women, or women of childbearing potential who do not use a highly effective form of birth control
  • Expected life expectancy < 6months
  • Drug or alcohol abuse
  • Inability to understand and sign study information and patient informed consent

Both women and men will be enrolled, and sex-specific differences in treatment effects will be examined in a subgroup analysis. No vulnerable populations will be included. All participants are capable of judgment.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Diltiazem

133 patients are randomized to the experimental intervention and treated with the non-dihydropyridine calcium channel blocker (NDCC) Diltiazem.

Study participants randomized in the experimental intervention group will receive Non-dihydropyridine calcium channel blockers (NDCC) Diltiazem retard for 90 days. Depending on the dosage of the beta-blocker treatment of these patients at baseline, three different dosage options will be used (low, normal, high). Diltiazem capsules of 90mg will be provided, meaning that patients with the low dosage will take one capsule a day (morning), patients with the normal dosage two capsules a day (morning and evening) and patients with the high dosage four capsules a day (2x morning and 2x evening). Based on previous data, we assume that most patients will use the low or normal dosage. The medication Diltiazem 90mg will be over-encapsulated, packed and labelled by a pharmacy specialist.

Comparatore attivo: Bisoprolol

133 patients are randomized to the control arm and treated with the beta-blocker Bisoprolol.

Study patients will receive the beta-blocker (BB) Bisoprolol for 90 days. Depending on the dosage of the BB treatment of these patients at baseline, three different dosage options will be used (low, normal high). Low dosage of Bisoprolol is corresponding to 2.5mg, normal dosage to 5mg and high dosage to 10mg/day. Bisoprolol capsules of 2.5mg will be provided, meaning that patients with the low dosage will take one capsule a day (morning), patients with the normal dosage two capsules a day (morning and evening) and patients with the high dosage four capsules (2x morning and 2x evening). The medication Bisoprolol will be over-encapsulated, packed and labelled by a pharmacy specialist.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Atrial-Fibrillation-related Quality of Life
Lasso di tempo: From baseline to 3 months

Change in Atrial-Fibrillation-related Quality of Life between Non-dihydropyridine calcium channel blockers (NDCC) versus continuation of beta-blockers (BB) from baseline to 3 months in patients with Atrial-Fibrillation.

The primary outcome uses the AFEQT questionnaire:

The AFEQT 20-item questionnaire is a validated, AF-specific QoL tool. It assesses 4 domains: symptoms, daily activities, treatment concerns, and treatment satisfaction. The overall AFEQT score is calculated using the first 3 domains and ranges from 0 = worst to 100 = best QoL. Additionally, for each domain of interest, there is a corresponding subscale score: symptoms, daily activities, treatment concerns, and treatment satisfaction subscale scores. Each subscale ranges from 0 = worst to 100 = best QoL and is scored separately. The AFEQT questionnaire will be done at baseline before the intake of the first study drug and after three months of intervention.

From baseline to 3 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
NT-proBNP
Lasso di tempo: At Baseline and 3 months

Change in NT-proBNP levels measured at baseline and after 3 months.

NT-proBNP is released into the circulation in response to myocardial cell stretch. This biomarker is commonly used to evaluate the degree of heart failure in cardiac patients. Non-fasting blood samples will be taken at baseline before randomization and at the final study visit (4.7ml each). NT-proBNP levels will be measured in the laboratory of the respective study site by using an electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics, Switzerland). Furthermore, if patients provide consent, additional blood samples (serum, plasma and whole blood) will be taken, processed, frozen and stored at -80°C, according to the ethical guidelines concerning biobanking, at the Cardiovascular Research Institute Basel. These samples will be used for future genetic analyses and for the assessment of emerging biomarkers of interest in this context.

At Baseline and 3 months
6-minute walking test (6MWT) distance
Lasso di tempo: At baseline and 3 months

Change in 6MWT distance assessed at baseline and after 3 months

The 6MWT is a simple test which does not require expensive equipment or advanced training for technicians. The test involves asking the patient to walk the longest distance possible in a set interval of 6 minutes, through a walking course (corridor) preferably 30 meters long. The result of the 6MWT will be entered in the CRF as the distance in meters. In this context, other variables will be assessed, including the Borg Scale after the test and information on whether the test was done with a walking aid or must be terminated earlier. The 6MWT will be done at baseline before randomization and after 3 months of intervention.

At baseline and 3 months
Peak flow measurement
Lasso di tempo: At baseline and 3 months

Change in peak flow measured at baseline and at the study end visit after 90 days of study intervention. The patient will perform the test in a standing position. Study personnel will instruct the patient to inhale as deeply as possible and then exhale as forcefully and rapidly as they can. The measurement will be repeated three times, and the results of all three attempts will be recorded in the study database.

At baseline and 3 months
Hierarchical composite endpoint comprising
Lasso di tempo: Baseline to 3 months

A hierarchical win ratio will be calculated comparing participants between treatment groups using the following pre-specified hierarchy (in order of priority), all assessed as change from baseline to 3 months:

  • AF-related QoL
  • 6MWT distance
  • NT-proBNP
Baseline to 3 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Patrick Badertscher, PD Dr. med., University Hospital, Basel, Switzerland

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 novembre 2026

Completamento primario (Stimato)

1 ottobre 2029

Completamento dello studio (Stimato)

1 ottobre 2029

Date di iscrizione allo studio

Primo inviato

22 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

22 ottobre 2026

Primo Inserito (Effettivo)

29 ottobre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi